Abstract
Bioresorbable scaffolds (BRS) represent a novel horizon in interventional cardiology and may lead to some potential long-term advantages including the restoration of vasomotion, positive remodeling and a reduced incidence of late and very-late scaffold thrombosis (ScT). This technology, introduced to overcome limitations of current metallic drug-eluting stents (DES), is constantly and rapidly evolving with many companies working on bioresorbable devices. The aim of this review is to present an update on the most promising scaffolds that are under development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
